Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled glucose levels result in T2DM progression and enhanced risk of complications and mortality.
Interindividual variability in therapeutic response is partly due to genetic heterogeneity, and pharmacogenomics is the discipline that investigates how our entire genome influences individual responses to drugs, and more specifically, pharmacogenetics focuses on genetic variation at a population level, and how these variants can affect therapeutic outcomes and incidence of adverse effects. 3 
| RESEARCH METHODS
A literature search was performed using MEDLINE with the following Manual integration with the bibliography from the most extensive reviews on the topic has also been carried out. patients of novel diagnosis for decades; it produces durable antihyperglycemic effects independently of body weight, carries a low risk of hypoglycemia, and has robust cardiovascular safety profile. For all these reasons, MET is the first choice treatment recommended by guidelines and is suitable for combination therapies with all other hypoglycemic agents. It has been showed that genetic factors influence glycemic response to MET, with a heritability of 34% for the absolute reduction in HbA1c, adjusted for pretreatment values (Table 1) . 4 
| Associations at GWAS level of significance
In the first Genome Wide Association study (GWAs) of MET response performed in two independent subsets of the GoDART cohort and in the UKPDS, both composed of European subjects affected by T2DM, the C allele of rs11212617 was found to be associated with reduced glycemic response to MET (odds ratio [OR] for the ability to achieve a treatment HbA1c <7% in the 18 months after starting MET = 1·35 95% CI 1·22-1·49). 5 rs11212617 is located downstream the gene coding for the ATM serine/threonine kinase, associated with ataxia telangiectasia. After discovery, the researchers were able to link ATM to MET action through functional studies in vitro. 5 Although the
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genetic association was confirmed through a meta-analysis of five cohorts from the United Kingdom and The Netherlands, 6 more recently, no significant differences in MET's effects by rs11212617 genotype on diabetes incidence or change in insulin sensitivity, fasting glucose levels, HbA1c, or disposition index were observed either in the large randomized control trial Diabetes Prevention Program (DPP) carried out in individuals with impaired glucose tolerance (IGT) 7 or in smaller studies. 8 It is possible that the latter population In a meta-analysis performed by the Metformin Genetics (MetGen) Consortium comprising 10 557 participants of European ancestry, a genome-wide statistically significant association was found for the intronic SNP rs8192675, located within SLC2A2, which encodes the GLUT2 glucose transporter. 10 Each copy of rs8192675
C allele was associated with a greater MET-induced HbA1c reduction of 0·17% (P = 6·6 × 10
), which was attenuated after adjusting for baseline HbA1c (reduction of 0·07%; P = 2 × 10
−8
). Consistent with the functional relevance of this variant, the C allele was associated with lower expression of GLUT2 in the liver. However, there was no effect of rs8192675 on the efficacy of MET in delaying progression to diabetes in the DPP study, again raising the possibility that MET × gene interaction in the prediabetic condition might change when T2DM is established.
| Associations replicated in multiple studies
Insulin signalling is triggered by the binding of insulin to the insulin receptor (IR). This activates the IR intrinsic tyrosine kinase activity and promotes tyrosine phosphorylation of IR substrate (IRS) proteins, which serve as a docking station for downstream signal transducers. 11, 12 The most frequent IRS1 variant is rs1801278 (Gly972Arg), [11] [12] [13] and the Arg972 allele is associated with early onset of T2DM; 14 IRS1 Gly972Arg polymorphism was found to be associated with failure to oral hypoglycemic treatment, mostly MET and SUF, in three Italian case-control studies. [15] [16] [17] The relationship between Gly972Arg and efficacy of MET in lowering HbA1c was explored in a small sample of Caucasian T2DM patients, and it returned no significant associations.
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The Organic Cation Transporter 1 (OCT1), encoded by SLC22A1 is the main transporter of MET, and highly polymorphic in humans, 19 55 Using knockout experiments on mice, it has been revealed that alterations of SLC47A1 sequence on both chromosomes are required in order for MET to accumulate in the liver, fostering lactic acidosis. 56, 57 It is, then, likely that inconsistencies about the effects of rs2289669 and rs622342 might depend on other, more dramatic, mutations of SLC47A1, occurring at an independent site, such as the five nonsynonymous variants, identified in a multiethnic nondiabetic cohort, associated with reduced MET transport in vitro [58] [59] [60] : rs77630697 (Gly64Asp), rs77474263 (Leu125Phe), rs35790011 (Val338Ile), rs76645859 (Val480Met), and rs35395280 (Cys497Phe). 58 Additionally, three nonsynonymous variants were demonstrated to be associated with reduced MET transport in vitro:
rs149774861 (Asp328Ala), the extremely rare mutation Ala310Val, and rs35646404 (Thr159Met) exclusive of Asiatic populations. 59, 60 SLC47A2 encodes for the transporter MATE2, highly homologous to MATE1, and, as the latter, is involved in excretion of endogenous and exogenous toxic electrolytes through urine and bile. Several non-synonymous variants in SLC47A2 sequence exhibited reduced MET transport activity in vitro: The transcript in presence of the rare mutations Lys64Asn, 59 rs562968062 (Gly211Val), 57, 59 and rs146901447 (Pro162Leu) 57 were not detectable in engineered HEK293 cells, while Tyr273Cys was localized to the wrong cellular compartments. 57 By contrast, the variant Pro162Leu seemed to increase the response to MET in vivo in a cohort of African American subjects. 61 The rare mutation Pro103Arg was found to be correctly expressed at the plasma membrane and to overdouble MET transport activity. 57 Finally, rs34399035 (Gly429Arg) was the only nonsynonymous variant apparently affecting the long-term decrease in HbA1c in European Caucasians, with carriers of the variant showing a 0·8% (95% CI, 0·02-1·6; P = 0.05) lower decrease than the wild-type carriers. 55 The intronic polymorphism rs12943590 was associated with reduced clinical response to MET in US diabetic subjects of African or European ancestry.
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The non-coding variant rs12943590, in the 5' UTR, was found to induce no pharmacokinetic differences in Koreans 41 and in a large meta-analysis performed on European T2DM subjects; 29 nevertheless, a small group of Korean nondiabetic volunteers carrying rs12943590 or rs758427 and rs34834489 exhibited increased promoter activity, with a significant raise in renal and secretion clearance. 
| Associations replicated in multiple studies
The gene CYP2C8 encodes for an enzyme belonging to the cytochrome P450 (CYP) superfamily. In presence of the most diffused dyplotype, CYP2C8*3, defined by the variants rs11572080
(Arg139Lys) and rs10509681 (Lys399Arg), repaglinide metabolism was reported to be increased, 65, 66 resulting in reduced drug bioavailability. 67 By contrast, the frequency of CYP2C8*3 carriers was reported to be higher in a small group of T2DM patients who experienced hypoglycemic events while undergoing treatment with SUF (glimepiride, gliclazide, or glipizide) in respect to wild-type CYP2C8*1 homozygous subjects, but this difference was not statistically significant. 68 The closely related CYP2C9 enzyme is the major responsible for SUF breakdown. The non-synonymous variants rs1799853 (Arg144Cys) and rs1057910 (Ile359Leu), respectively defined as CYP2C9*2 and CYP2C9*3, have been reported to determine lower-CYP2C9 catalytic activity, [69] [70] [71] [72] Caution should be advised when interpreting these data because it has been recently demonstrated that CYP2C9 catalytic impairment might be counteracted by the effects of genetic variation at the CYP oxidoreductase (POR) gene, which is tightly associated with CYP enzymes and can modulate their activity; 86 indeed, in a subset of subjects from the GoDART database, it has been reported that the number of CYP2C9*2 and *3 alleles was associated with nearly three-fold increased risk of hypoglycaemic events and better response to SUF only in patients carrying the POR*1/*1 wild-type genotype. 87 The solute carrier organic anion transporter 1B1 (SLCO1B1)
encodes for a transmembrane receptor protein, called OATP1B1, involved in the removal of anionic compounds from the blood into the hepatocyte. SLCO1B1 locus is highly polymorphic; its best characterized non-synonymous variant, rs4149056 (Val174Ala), has been demonstrated to significantly increase repaglinide bioavailability in both T2DM and healthy subjects of Caucasian and Asian ethnicity. 65, [88] [89] [90] [91] [92] [93] A larger concentration of nateglinide in the presence of the low-metabolizing variant 174Ala has also been reported, 72, 94 but the association has not been consistent throughout other studies.
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The non-coding SNP rs4149015, located less than 1 kb upstream SLCO1B1 has been found to be associated with an increased glucose-lowering effect of repaglinide, 65 an effect that could be attributed to the close proximity with rs4149056 polymorphism. associated with early failure of SUF therapy in a cross-sectional study performed on a small cohort of T2DM patients. 99 T2DM patients on SUF treatment carrying the G/G genotype of the synonymous SNP rs1799859 (Arg1273Arg) had significantly higher-HbA1c levels compared with the patients with A/A genotype, 98 thus implying lower-SUF efficacy. In the same study, no effect of rs757110 (Ala1369Ser) was observed on SUF ability to modulate either fasting and postprandial glucose levels or HbA1c. 98 The latter result has been confirmed in several studies across different ethnicities. 82 84 The intronic variant rs12742393 has been associated with T2DM in a cohort of Chinese patients with the C allele showing significant risk for diabetes with an OR of 1·17 (95% CI, 1·07-1·26, P = 0.0005). 133 Indeed, the effects of repaglinide treatment on fasting plasma glucose, insulin levels, and HOMA-IR index were reduced in patients with T2DM carrying the NOS1AP rs12742393 risk C allele compared with carriers of the AA genotype. 134 As anticipated in Section 3.1.2, IRS1 plays a pivotal role in the transduction of the insulin signalling cascade. The most frequent variant of IRS1, Gly972Arg, was found to be associated with failure of the hypoglycemic treatment with SUF in five case-control studies. [15] [16] [17] [18] 120 Furthermore, diabetic patients carrying the Arg972 variant receiving treatment with insulinotropic hypoglycaemic drugs such as SUF and/or glinides had higher-HbA1c levels compared with wild-type carriers. 18 In vitro experiments performed on a rat beta-cell line and isolated human islets have proven that the risk allele 972Arg is associated with a marked reduction of insulin secretion in response to SUF. 135, 136 The locus of transcription factor 7-like 2 gene (TCF7L2) is the strongest known signal associated with T2DM. 137 Consistent evidences have been reported for the intronic polymorphisms of TCF7L2 (rs12255372 and rs7903146) with increased risk of T2DM. [138] [139] [140] [141] Both risk alleles have also been associated to reduced response to SUF treatment in a large randomized control trial on European subjects, 142 and rs7903146 polymorphism was associated to SUF treatment failure in an independent study on T2DM German patients. 143 A pharmacogenetic study in Asian subjects has assessed the effects exerted on glimepiride hypoglycemic efficacy by several intronic variants in the TCF7L2 locus, in a small number of healthy volunteers 84 ; the SNPs rs290487, rs11196205, and rs12255372, along with rs7903146, showed no differences when compared with the wild-type alleles, 84 although the variant rs290487 had previously been identified as a modulator of repaglinide therapeutic action in Chinese T2DM patients. 
| Polymorphisms affecting TZDs response
Since the late 1990s, TZDs are a therapeutic option for patients with T2DM in whom they act by improving insulin sensitivity and preserving β-cell secretory function. The net effect of TZDs is an increased mass of small insulin-sensitive subcutaneous adipocytes with decreased lipolytic activity, resulting in decreased free fatty acids concentration and improved adipocytokine profile. 145 Similarly to SUF and insulin treatment, TZDs may lead to weight gain, partly because of TZDs' most common side effect, fluid retention, which might foster the formation of peripheral edema in patients with cardiac or renal disease. 146 The docking of PPARG to the transcription factor coactivator PPARGC1A allows the recruitment of two transcription factors to form a highly efficient transcription complex. In Chinese T2DM patients, the non-synonymous polymorphisms (Thr394Thr; rs2970847 and Gly482Ser; rs8192678) in PPARGC1A appear to influence patient response to ROSI therapy. 158, 173, 181 To date, no significant differences were observed when the effects of Gly482Ser were evaluated in patients treated with PIO. glucose levels. 182, 183 Another study conducted in diabetic subjects from Southern China has shown that the synonymous T45G polymorphism at rs2241766 (Gly15Gly) is related to PIO response in T2DM
with patients carrying the TG genotype exhibiting a greater reduction in HbA1c, 184 whereas no evidence of pharmacogenetic influence on HbA1c or fasting glucose levels was observed in response to PIO treatment in Iranian T2DM patients. 185 Together with rs2241766 polymorphism, the intronic SNP rs1501299 has been shown to be associated with reduced fasting glucose and HbA1c levels after ROSI therapy, 186 while opposing evidences were reported in a large cohort of Chinese patients in which the therapeutic efficacy of multiple-dose ROSI was assessed. cascade. [188] [189] [190] Adverse effects induced by GLP-1R agonists include transient nausea, vomiting, and diarrhoea, 191 although prescription to patients with a history of pancreatitis, medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2 should be made with caution (Table 4) . 192 
| Associations at GWAS level of significance
Although several naturally occurring non-synonymous polymorphisms in the gene coding for gastric inhibitory polypeptide receptor (GIPR) have been characterized, the polymorphism rs13306399 (Cys46Ser) was the only one capable of altering the binding of GIP, 193 while both rs13306399 and rs13306403 (Arg316Leu) have been shown to decrease GIP sensitivity in beta cells in vitro. 193 The same polymorphisms, together with the infrequent variants rs13306398
(Gly198Cys) and rs1800437 (Glu354Gln), are also associated with reduced cell surface expression and basal receptor signalling. Polymorphism rs1800437 was further involved with cardiovascular disease incidence 194 and cultured adipocytes carrying the rs1800437 minor C allele manifested a drastic downregulation of the receptor desensitization-resensitization cycle. 195 The A allele of the intronic variant rs10423928 was associated with a lower amount of the splicing isoform required for transmembrane activity. 196 Recently a 6 months follow-up study carried out in a small group of T2DM patients found no evidence of association with DPP-4 inhibitors efficacy, 197 although carriers of the A allele had been reported to exhibit 0·09 (CI, 0·07-0·11) mmol/L increase of 2-h postload glucose levels during an OGTT, decreased insulin secretion, and a diminished incretin effect in vivo in large cohort studies, 198, 199 aside of a reduction in body mass index (BMI), lean body mass, and waist circumference.
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A molecular connection with osteopontin (OPN) was suggested because carriers of rs10423928 had lower-OPN expression in pancreas and adipose tissue, both GIP and OPN modulate cytokineinduced apoptosis. 196, 199 The intron variant rs2287019, falling within the glutaminyl-peptide cyclotransferase-like (QPCTL) gene, approximately 15 kb downstream GIPR, has been associated with BMI at genome-wide level. 200 The risk C allele was also reported to be associated with higher fasting glucose but lower 2-h postload glucose concentrations during an OGTT. 198, 201 Taken together, these findings suggest that GIPR variants could potentially modulate the response to DPP-4 inhibitors, nevertheless, to date, this effect has not been revealed by clinical studies. 194, 197, 202 The GLP-1 receptor is an important drug target for the treatment of T2DM, and several non-synonymous variants of GLP1R have been carefully characterized: rs367543060 Thr149Met variant, identified in one Japanese diabetic subject, 203 induces a significant loss of function in vitro [204] [205] [206] and impairs the insulin secretory response to GLP-1 in vivo. 203, 206 The polymorphism rs10305493 (Ser333Cys) instead has been proven to preserve peptide response. 205, 206 The SNP rs6923761 (Gly168Ser) was nominally associated with reduced insulin secretion in response to GLP-1 infusion during a hyperglycemic clamp in nondiabetic American subjects 207 and with a weaker response to the glucose-lowering effect of DPP-4 inhibitors in patients with T2DM. 197 On the contrary, the same polymorphism was associated with higher efficacy of liraglutide, 208 and it was shown to increase weight and fat mass loss after liraglutide treatment, 209 ,210 different types of diet, 211 or bilio-pancreatic diversion surgery. 212 In addition, carriers of the rs6923761 A allele had higher basal GLP-1 levels 210 and a better cardio-metabolic profile. 213 When the dyplotype rs6923761 (Gly168Ser)/rs10305420 (Pro7Leu) was studied, the wild-type form 7Pro, combined with the mutated 168Ser appeared to give an even bigger contribution to the efficacy of treatment with liraglutide. 208 Heterozygous carriers of the minor allele of rs3765467 (Arg131Gln) were reported to have higher betacell response to GLP-1 infusion during a hyperglycemic clamp, 207 but no significant differences were observed when genotypes at rs3765467 and rs761386 (an intronic variant in perfect linkage disequilibrium with the intronic short tandem repeat at rs5875654 8GA/7GA) were compared in relation to changes in plasma glucose levels after exenatide treatment. Finally, the minor (A) allele of the low-frequency rs10305492 (Ala316Thr) was associated at genomewide level with lower fasting glucose levels, [214] [215] [216] and lower risk of T2DM, but lower early insulin secretion and higher 2-h glucose during an OGTT. 216 
| Associations replicated in multiple studies
As anticipated in Section 3.2.1, KCNQ1 channels are involved not only with the mechanisms of insulin secretion but also in GLP-1 and GIP release from the intestinal endocrine cells. 217 In a small pilot study, KCNQ1 polymorphisms rs163184 G was associated with lower-HbA1c reduction in response to DPP4 inhibitors treatment, 218 consistent with previous findings in European, 125 South American, 126 and Asian 123, 124 subjects. rs2237895, rs151290, rs2237892, and rs2237897, all falling within the same intron as rs163184, were found to be associated with several OGTT-derived indexes of insulin secretion, although not during the intravenous glucose tolerance test (IVGTT), in nondiabetic subjects. 219 Regardless, nondiabetic individuals homozygous for the diabetes protective allele (A) at rs151290
exhibited lower-active GLP-1 concentrations at 10 minutes during the OGTT. 230 In addition to this, we are unaware of how most of those susceptibility loci contribute to diabetes incidence, especially in the case of non-coding polymorphisms or genes that do not translate into proteins; therefore,
we are yet incapable of exploiting them as drug targets for functional intervention on the disease.
Genetic investigation has also been dedicated to evaluate the interindividual variability in the response to oral and injectable glucose-lowering agents, and in recent years, many pharmacogenetic studies of associations between genetic variants and glucose-lowering drug response have been published. To a large extent, these studies were designed to identify subsets of subjects more or less likely to experience therapeutic response to the drug in question or to develop side effects. Indeed, the care of patients with T2DM requires an individualized approach because of the fact that the disease is heterogeneous, alterations in molecular and pathophysiological pathways of glucose homeostasis differ between subjects, and the variable effects of existing therapies make it difficult to predict individual response to glucose-lowering medications. 231 Clearly, an individualized approach is important because of the multitude of clinical features involved in decision-making including age, body weight, disease duration, life expectancy, glycemic control history, risk of hypoglycemia, adverse effects of glucose-lowering medications, presence of complications and comorbid conditions, and psycho-socio-economic factors. 232, 233 Througout this review, it was definetly shown how ethnicity is also a major determinant of the outcomes. [234] [235] [236] The usual approach for 
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